Open AccessExpression of PLK1 and survivin in non‐Hodgkin's lymphoma treated with CHOP
Author(s) -
LIU Lin,
ZHANG Min,
ZOU Ping
Publication year - 2008
Publication title -
acta pharmacologica sinica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.514
H-Index - 90
eISSN - 1745-7254
pISSN - 1671-4083
DOI - 10.1111/j.1745-7254.2008.00750.x
Subject(s) - survivin , lymphoma , plk1 , cancer research , medicine , lactate dehydrogenase , chop , immunohistochemistry , oncology , biology , cancer , enzyme , cell cycle , biochemistry
Aim: The present study was designed to investigate the expression of Polo‐like kinase 1 (PLK1) and survivin in non‐Hodgkin's lymphoma (NHL). Methods: The expression of PLK1 and survivin were detected with immunohistochemical techniques. Results: The expression rate of PLK1 and survivin were 63.6% (56/88) and 79.5% (70/88) in NHL, respectively. PLK1 expression correlated with systemic symptoms, lactate dehydrogenase levels, and international prognostic index scores in B‐NHL and T‐NHL, while survivin did not. Conclusion: PLK1 and survivin are both overexpressed in NHL. There is a significant relationship between the overexpression of PLK1 and clinical features.